BUSINESS
Eisai Aims to Turn Leqembi to Black in FY2026 with EU Approval as Tailwind: CEO
May 16, 2025
Eisai sees its Alzheimer’s drug Leqembi (lecanemab) following a growth trajectory globally, with the business expected to turn into the black in the fiscal year through March 2027 (FY2026), CEO Haruo Naito said at an…

LATEST

May 16, 2025
A group of former Diet members well versed in healthcare policymaking issued a proposal on pharmaceutical policies on May 13, which calls for the revamp of the cost-effectiveness assessment (CEA) scheme and a new drug…
May 16, 2025
Japan faces the need to boost its innovative capabilities as its global presence as a pharmaceutical originator is diminishing, Former Prime Minister Fumio Kishida said on May 14, calling for the challenge to be addressed…
May 16, 2025
The Pharmaceuticals and Medical Devices Agency (PDMA) said on May 14 that the label of Gilead Sciences’ anti-HIV drug Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide fumarate) has been updated to expand the range of…
By Hayate Horiguchi

The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…

By Philip Carrigan

The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

By Ken Yoshino

Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…

For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…

A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA